

## Novugen Launches Macitentan in the U.S.

Novugen has successfully launched Macitentan in the United States, further strengthening our growing presence in one of the world's most highly regulated pharmaceutical markets.



Macitentan, an endothelin receptor antagonist (ERA), is indicated for the treatment of Pulmonary Arterial Hypertension (PAH, WHO Group I) in adults, helping reduce the risks of disease progression and hospitalization.

This milestone marks a significant step forward in expanding access to high-quality cardiovascular therapies in the U.S. market, valued at approximately USD 1.1 billion (IMS 2025). Developed in strategic partnership with Seasons Biotechnology, Novugen is proud to be among the first-to-file applicants, reinforcing our commitment to complex generics and our growing cardiovascular portfolio.

This achievement further advances our efforts to deepen engagement with healthcare professionals and improve patient outcomes in chronic and high-burden disease areas. With scientific excellence and a strong resolve to challenge the status quo, we remain committed to our mission of bringing accessible medicines to patients worldwide while upholding the highest global regulatory and quality standards.